Overview

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Status:
Active, not recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
BioMed Valley Discoveries, Inc